Experimental cell therapy targets tough cancers, but trial ends early
NCT ID NCT03745326
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a new approach: taking a patient's own white blood cells, genetically modifying them in the lab to recognize a specific cancer mutation (KRAS G12D), and infusing them back to attack tumors. The study enrolled only 5 adults with advanced gastrointestinal cancers. The trial was terminated early, so we have limited information on safety and effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- genetically modified immune cells (anti-KRAS G12D murine T-cell receptor cells)
- What this could lead to
- If successful, this approach could point toward a new treatment for hard-to-treat cancers with a specific KRAS mutation.
- What could go wrong
- This trial was terminated early with only 5 participants, so results are very limited. The therapy involves strong chemotherapy and carries risks of severe side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLON CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Can a plasma beam stop colon polyps from coming back?
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- A stitch in time: could a device make abdominal closure safer?
- Could deep breaths before surgery ward off Post-Op confusion?
- Digital nurse companion: could an app ease the burden of chronic illness?